Table 3.
Logistic regression analyses: Factors able to predict nivolumab concentrations <18.7 μg/mL at 15 days of therapy. Bold represents statistically significant values. NC: not comparable, all the factors belong to a single group. Thus, statistics could show p-values and odd-ratio (OR).
| Variables | Nivolumab Concentrations ≤ 18.7 μg/mL | |||
|---|---|---|---|---|
| Univariate | Multivariate | |||
| p-Value | OR (95% IC) | p-Value | OR (95% IC) | |
| BMI < 25 Kg/m2 | 0.766 | 1.270 (0.392–6.112) | ||
| Age > 60 years | 0.939 | 0.970 (0.091–9.145) | ||
| Gender (male) | 0.213 | 2.260 (0.692–12.419) | ||
| Drug dosage < 200 mg | 0.945 | 1.056 (0.099–4.867) | ||
| VDBP (GC) AC/CC | 0.059 | 11.667 (0.909–149.700) | 0.049 | 10.667 (0.830–137.145) |
| CYP24A1 3999 CC | NC | |||
| VDR TaqI TC/CC | 0.164 | 3.077 (0.632–14.976) | ||
| CYP27B1 -1260 GG | 0.148 | 3.250 (0.658–16.040) | ||
| Pre 25-hydroxyvitamin D levels | NC | NC | ||
| Pre 1,25-hydroxyvitamin D levels | 0.124 | 3.840 (0.692–21.312) | ||
| Adenocarcinoma NSCLC type | NC | |||
| Squamous cell carcinoma | NC | |||
| Cisplatine pre-treatment | 0.093 | 4.442 (0.852–24.853) | ||
| Carboplatine pre-treatment | 0.190 | 0.300 (0.051–1.854) | ||
| Pemetrexed pre-treatment | NC | |||